Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA ...

Delivered Q3 2025 revenue of $83 millionQ32025 non-dermatologic revenue increased by 67% over Q32024Q32025 total test reports ...

Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need ...

China’s dominance of the rare earth metals business—with a chokehold on Western militaries and key industries—has become a key geopolitical issue. Chinese companies make most of the parts that go into ...